SEC Form 4 · accession 0000950138-18-000020
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Trudeau
Officer — President and CEO · Director
Period of report
Jan 2, 2018
Accepted (ET)
Jan 4, 2018 · 7:08 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 2, 2018 | A | 10,046 | $0.00 | A | 279,424 | D | |
| Ordinary Shares | Jan 2, 2018 | F | 6,511 | $23.52 | D | 272,913 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Vesting of performance share award granted on January 2, 2015.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.